Literature DB >> 2810332

3-Sulfonyl-1-carba-1-dethiacephems.

T A Crowell1, B D Halliday, J H McDonald, J M Indelicato, C E Pasini, E C Wu.   

Abstract

The stability of the 1-carba-1-dethiacephalosporin framework has allowed the synthesis of a range of 3-sulfonyl-1-carba-1-dethiacephems unavailable for a variety of reasons in the cephem arena. The known p-nitrobenzyl 7 beta-(phenoxyacetamido)-3-[[(trifluoromethyl)sulfonyl]oxy]-1-carba -1- dethia-3-cephem-4-carboxylate served as a precursor to this series of compounds. Displacement of the enol triflate with various sulfinates in acetonitrile or DMF and deprotection of the intermediates led to 7 beta-[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]- 3-[alkyl(aryl)sulfonyl]-1-carba-1-dethia-3-cephem-4-carboxyl ic acids. The 3-sulfonyl-1-carba-1-dethiacephems display potent activity against both Gram-positive and Gram-negative bacteria. The following MIC's (microgram/mL) for the 3-cyclopropyl sulfone are representative: Staphylococcus aureus = 4, Streptococcus pyogenes = 1, Haemophilus influenzae = 0.25, Escherichia coli = 0.03, Enterobacter cloacae = 0.25, Proteus rettgeri = 0.25. The excellent in vitro antibacterial activity of this series indicates the potential of the carbacephalosporin framework for exploring substituents which are unknown or which produce unstable cephems.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2810332     DOI: 10.1021/jm00131a005

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Loracarbef versus penicillin V in the treatment of streptococcal pharyngitis and tonsillitis.

Authors:  O Müller; Z Spirer; K Wettich
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

2.  Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.

Authors:  O Müller; K Wettich
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

Review 3.  Acute bronchitis: results of U.S. and European trials of antibiotic therapy.

Authors:  W H Dere
Journal:  Am J Med       Date:  1992-06-22       Impact factor: 4.965

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.